Exenatide pegylated analogue - PegBio

Drug Profile

Exenatide pegylated analogue - PegBio

Alternative Names: PB-119; PEG-exenatide

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PegBio
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (SC, Injection)
  • 09 Jun 2017 Pharmacokinetics, Pharmacodynamics and adverse events data from a phase I trial in Type 2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 15 Nov 2016 PegBio completes a phase I trial in Type 2 diabetes mellitus in USA (NCT03072407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top